AstraZeneca Leads Bid for Abivax as Eli Lilly Waits in the Wings

AstraZeneca gains exclusive data access to acquire surging French biotech Abivax (up 1,600% in 2025) before March 23 deadline; Eli Lilly waits in wings amid IBD drug promise.